Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis - Daniels, G H; Vladic, A; Brinar, V; Zavalishib, I; Valente, W; Oyuela, P; Palmer, J; Margolin, D H; Hollenstein, J (J Clin Endocrinol Metab, 2014)